ERBB2 and neoplasm: Regarding the differences between primary tumor and circulating tumor cells, and the dynamic change in CTCs during the course of the disease, three studies [24,25,26] reported an increase in Her2-positive CTCs during therapy, even when the primary tumor was Her2-negative.